The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B-Reference-Cited by-同舟云学术

The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B

Published:2021-05 Issue: Volume:Volume 8 Page:467-476
ISSN:2253-5969
Container-title:Journal of Hepatocellular Carcinoma
language:en
Short-container-title:JHC

Author:

Lee Hye Won,Lee Hyun Woong^ORCID,Lee Jae Seung,Roh Yun Ho^ORCID,Lee Hyein^ORCID,Kim Seung Up^ORCID,Park Jun Yong,Kim Do Young,Ahn Sang Hoon,Kim Beom Kyung

Publisher

Informa UK Limited

Subject

General Medicine

Reference46 articles.

1. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

2. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population

3. Korean Association for the Study of the Liver (KASL) clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol. 2019;25(2):93–159. doi:10.3350/cmh.2019.1002

4. Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop

5. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liver and spleen stiffness measurement in the prediction of hepatocellular carcinoma in chronic liver disease;Exploration of Digestive Diseases;2024-08-21

2. Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy;Journal of the Formosan Medical Association;2023-12

3. External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study;Cancers;2022-01-29